Evaluation of gabapentin as a pre-emptive analgesic for patients undergoing total hip arthroplasty

Completed

Conditions: Pre-emptive pain medication/postoperative pain control
Signs and Symptoms
Pain

Registration Number: ISRCTN14907042

Lead Sponsor: Sunnybrook Health Sciences Centre (Canada)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 90

Inclusion Criteria

Upon obtaining informed consent, patients with American Society of Anesthesiologists physical status I and II, of both genders, scheduled for hip arthroplasty will be recruited for this double-blinded, prospective, randomized, and placebo-controlled study. Patients must also be 18?70 years of age.

Exclusion Criteria

1. Patients not providing informed consent
2. Patients less than 18 years of age and greater than 75 years of age
3. Known allergy to any of the medications being used
4. History of drug or alcohol abuse
5. Patients with chronic pain on slow-release preparations of opioid
6. Patients with rheumatoid arthritis
7. Patients with psychiatric disorders
8. Patients unable or unwilling to use patient-controlled analgesia
9. Diabetic patients or those with impaired renal function (creatinine >106)
10. Obese patients (i.e., body mass index [BMI] >40)

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A comparison of the means of morphine consumption among the various treatment groups will be the primary outcome measure.

Secondary Outcome Measures

Name	Time	Method
1. Visual Analog Scale (VAS) for pain will be used (0 = no pain, 100 = terrible pain)<br>2. Presence of nausea, vomiting, pruritis, and dizziness will be monitored at the same time intervals, and all except the latter treated as per the Acute Pain Service Nausea and Vomiting algorithm